Welcome to our dedicated page for Precigen news (Ticker: PGEN), a resource for investors and traders seeking the latest updates and insights on Precigen stock.
Precigen, Inc. reports developments as a commercial-stage biopharmaceutical company advancing precision medicines for difficult-to-treat diseases. Its news centers on PAPZIMEOS (zopapogene imadenovec-drba), an FDA-approved therapy for adults with recurrent respiratory papillomatosis, including commercialization, access, reimbursement, medical-publication updates, and adoption by treating physicians.
Company updates also cover financial results, business presentations, and pipeline activity across immuno-oncology, autoimmune disorders, and infectious diseases. Precigen’s recurring technology references include the AdenoVerse immunotherapy platform, UltraCAR-T programs, and related manufacturing capabilities used to support its precision-medicine portfolio.
Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company, will release its second quarter and first half 2020 financial results on August 10, 2020, after market close. A conference call will follow at 4:30 PM ET to discuss these results along with a general business update. Precigen focuses on innovative gene and cell therapies targeting critical diseases, maintaining a preclinical and clinical pipeline. The company emphasizes its commitment to advancing precise, affordable biotherapeutics for various medical challenges.
Precigen announced preclinical data for its investigational PRGN-3005 UltraCAR-T aimed at treating advanced ovarian cancer, presented during the AACR Virtual Annual Meeting II. The data indicates that UltraCAR-T, generated through a rapid, non-viral process, shows superior efficacy and persistence compared to traditional CAR-T therapies. In preclinical trials, all treated mice became tumor-free after receiving PRGN-3005, and the treatment demonstrated durability upon tumor rechallenge. The FDA has approved the IND for a Phase I clinical trial that is currently underway.